News Releases

Email Alerts

Feb 16, 2017

Insmed to Host Fourth Quarter and Year-end 2016 Financial Results Conference Call on Thursday, February 23, 2017

BRIDGEWATER, N.J., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
Feb 14, 2017

Insmed Inc. Extends ARIKAYCE Intellectual Property Protection with Issuance of New U.S. Patent

BRIDGEWATER, N.J., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
Jan 4, 2017

Insmed to Present at the 35th Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported...
Nov 14, 2016

Insmed to Participate at November Investor Conferences

BRIDGEWATER, N.J., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported...
Nov 3, 2016

Insmed Reports Third Quarter 2016 Financial Results and Provides Business Update

Enrollment objective achieved in phase 3 CONVERT study

BRIDGEWATER, N.J., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported...
Oct 27, 2016

Insmed to Host Third Quarter 2016 Financial Results Conference Call on Thursday, November 3, 2016

BRIDGEWATER, N.J., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases, today announced that...
Oct 18, 2016

Insmed Announces Publication of Phase 2 Study of ARIKAYCE in Treatment-Refractory Nontuberculous Mycobacterial Lung Disease

Data in American Journal of Respiratory and Critical Care Medicine demonstrate ARIKAYCE's potential to achieve early and sustained negative sputum cultures

BRIDGEWATER, N.J., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
Oct 5, 2016

Insmed Announces Worldwide License Agreement with AstraZeneca for Oral DPP1 Inhibitor

BRIDGEWATER, N.J., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
Sep 27, 2016

Insmed Appoints Roger Adsett as Chief Commercial Officer

BRIDGEWATER, N.J., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
Sep 8, 2016

Insmed to Participate at September Investor Conferences

BRIDGEWATER, N.J., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...

Show per page